Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eczema study uncovers potential new treatment path

NCT ID NCT04133506

Knowledge-focused Sponsor: NHS Lothian Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at a specific immune pathway (PGE2/IL22/IL17) in people with eczema to see if it plays a role in the disease. Researchers collected skin and blood samples from 38 participants, including those with eczema, psoriasis, and healthy volunteers. The goal was to identify which patients might benefit from future treatments targeting this pathway.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

38 people

The number who actually took part.

Started

Nov 2021

Finished

Nov 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The investigators will require 12 from each of the three eczema groups: acute, chronic and Allergic Contact Dermatitis as well as 4 psoriasis patients and 4 samples from plastic surgery patients. This comes to a total of 44 patients. For healthy controls undertaking the dithranol/DNCB study the investigators will anticipate a group of 8 and when the investigators repeat the experiment and administer aspirin the investigators will divide these 8 patients into 4 who receive aspirin (a non-selective prostaglandin inhibitor) and 4 who do not receive aspirin. 44 patients (including the banked healthy skin of plastic surgery patients) +8 healthy volunteers= 52 as above.

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- Eczema patients must meet criteria of one of the following groups: Have eczema and attend the Edinburgh Dermatology Clinic. The normal control patients will be matched for age and sex as closely as possible to our eczema patients. The participants should be able to give informed consent and should be at least 16 years of age with no upper limit. Psoriasis patients: The participants will have a diagnosis of psoriasis and attend Edinburgh Dermatology clinic. Controls will be age and gender matched. There is no upper age limit, but the lower age limit is 16. Healthy volunteers: The participants should have no intolerance or allergy to aspirin and no allergy/sensitivity to dithranol or DNCB. There is no upper age limit but the lower age limit is 16. Exclusion Criteria: \- Eczema patients: 1. Treatment with systemic corticosteroids or other immune response modifying systemic drugs such as azathioprine or methotrexate 2 months before the study starts. 2. Inability to give informed consent. Psoriasis: 1. Treatment with systemic corticosteroids or other immune response modifying systemic drugs such as azathioprine or methotrexate 2 months before the study starts. 2. Inability to give informed consent. For healthy volunteers: 1. intolerance/allergy to aspirin and allergy/sensitivity to dithranol or DNCB. 2. involvement in another study at the same time. 3. pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Eczema are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema Eczema psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Eczema

Contacts and locations

Locations

  • QMRI

    Edinburgh, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.